<DOC>
	<DOCNO>NCT02116569</DOCNO>
	<brief_summary>The purpose study evaluate tolerability safety Daratumumab Japanese participant relapse ( return medical problem ) refractory ( respond treatment ) multiple myeloma ( cancer plasma cell bone marrow , characterize presence abnormal protein blood ) .</brief_summary>
	<brief_title>A Study Daratumumab Japanese Participants With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>This Phase 1 , open-label ( participant study personnel know identity study treatment ) multicenter ( study conduct multiple site ) study Japanese participant . The study include Screening Phase , Treatment Phase , Follow-up Phase . The Treatment Phase consist 2 part : intense dose regimen less intense dose regimen . Follow-up phase 8 week last dose administration/death/lost follow up/consent withdrawal study participation study end , whichever occur first . The primary endpoint Dose Limiting Toxicity ( DLTs ) overall Adverse Events ( AEs ) profiling . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participants prove symptomatic ( symptom ) multiple myeloma accord International Myeloma Working Group ( IMWG ) diagnostic criterion Participant must measurable disease define either follow measurement : ) Serum Mprotein great equal ( &gt; = ) 1 gram per deciliter ( g/dL ) ( &gt; =10 gram per liter [ g/L ] ) ( except serum immunoglobulin A [ IgA ] Mprotein &gt; = 0.5 g/dL ) ; b ) Urine Mprotein &gt; =200 milligram per 24 hour ( mg/24 h ) ; case immunoglobulin D [ IgD ] immunoglobulin E [ IgE ] Mprotein , quantification perform Participant must relapse refractory multiple myeloma receive least 2 previous therapy , without establish treatment option Participant must Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 Participant must life expectancy great ( &gt; ) 3 month Participant receive daratumumab anticluster differentiation 38 ( antiCD38 ) therapies previously Participant receive antimyeloma treatment within 2 week administration study drug Participant previously receive allogenic stem cell transplant ; participant receive autologous stem cell transplantation ( ASCT ) within 12 week administration study drug Participant history malignancy ( multiple myeloma ) within 5 year administration study drug Participant exhibit clinical sign meningeal involvement multiple myeloma</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Daratumumab</keyword>
	<keyword>JNJ-54767414</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Relapse</keyword>
	<keyword>Refractory</keyword>
</DOC>